Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | MYC | P01106 | 4/20 | 0.43 |
| ▸ | RORC | P51449 | 5/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114139 | 0.95 | CYP2C9 (0.51) | CYP2C9CYP2C19MYCRORCNSD2 | |
| SCHEMBL4113576 | 0.91 | CYP2C9 (0.56) | CYP2C9CYP2C19MYCNSD2JAK2 | |
| SCHEMBL13561250 | 0.88 | CYP2C9 (0.44) | CYP2C9CYP2C19RORCJAK2JAK1 | |
| SCHEMBL4111667 | 0.87 | CYP2C9 (0.46) | CYP2C9CYP2C19MYCRORCNSD2 | |
| SCHEMBL13561252 | 0.85 | CYP2C9 (0.47) | CYP2C9CYP2C19JAK2JAK1TYK2 | |
| SCHEMBL4110938 | 0.84 | CYP2C9 (0.55) | CYP2C9CYP2C19MYCRORCNSD2 | |
| SCHEMBL13561273 | 0.84 | CYP2C9 (0.55) | CYP2C9CYP2C19MYCNSD2JAK2 | |
| SCHEMBL3838917 | 0.83 | CYP2C9 (0.56) | CYP2C9CYP2C19MYCRORCNSD2 | |
| SCHEMBL4100103 | 0.83 | CYP2C9 (0.47) | CYP2C9CYP2C19RORCKCNH2CYP3A4 | |
| SCHEMBL4105748 | 0.83 | CYP2C9 (0.51) | CYP2C9CYP2C19MYCRORCNSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | Andrea Boesciences, Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | Andrea Boesciences, Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | Andrea Boesciences, Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2220091-B1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2220091-B1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2012-07-25 | — | — | EP | disclosed |
| US-8207178-B2 | Fused pyrimidines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207178-B2 | Fused pyrimidines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207178-B2 | Fused pyrimidines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| WO-2009079412-A2 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | CYP2C9 2156/4885CYP2C19 1979/4885MYC 2371/4885 |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | CYP2C9 2156/4885CYP2C19 1979/4885MYC 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.